Briakinumab is a monoclonal antibody that targets interleukin-23 (IL-23), a cytokine involved in inflammatory processes. It is primarily developed for the treatment of autoimmune diseases, particularly psoriasis and other inflammatory conditions. As a biologic agent, briakinumab is produced using recombinant DNA technology and is designed to inhibit the activity of IL-23, thereby modulating the immune response and reducing inflammation. The molecular structure of briakinumab consists of a large protein framework, which includes variable regions that confer specificity to IL-23. Its pharmacokinetics typically involve a longer half-life compared to small molecule drugs, allowing for less frequent dosing. Commonly administered via subcutaneous injection, briakinumab may have side effects related to immune suppression, such as increased susceptibility to infections. Overall, its mechanism of action and therapeutic applications make briakinumab a significant option in the management of chronic inflammatory diseases.

Briakinumab

339308-60-0: Briakinumab is a monoclonal antibody that targets interleukin-23 (IL-23), a cytokine involved in inflammatory processes. It is primarily developed for the treatment of autoimmune diseases, particularly psoriasis and other inflammatory conditions. As a biologic agent, briakinumab is produced using recombinant DNA technology and is designed to inhibit the activity of IL-23, thereby modulating the immune response and reducing inflammation. The molecular structure of briakinumab consists of a large protein framework, which includes variable regions that confer specificity to IL-23. Its pharmacokinetics typically involve a longer half-life compared to small molecule drugs, allowing for less frequent dosing. Commonly administered via subcutaneous injection, briakinumab may have side effects related to immune suppression, such as increased susceptibility to infections. Overall, its mechanism of action and therapeutic applications make briakinumab a significant option in the management of chronic inflammatory diseases.

Briakinumab (ABT-874) is a monoclonal antibody targeting IL-12, used in the research of psoriasis multiple sclerosis.

Anti- IL-12 and IL-23 human monoclonal antibody; used to treat rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis

CAS 339308-60-0

Briakinumab

Briakinumab

Ref: TM-T76935

Briakinumab

Ref: 3D-CLA1131